New CGM device aims to simplify diabetes management

NCT ID NCT06904846

ENROLLING_BY_INVITATION Disease control Sponsor: Sinocare Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a new continuous glucose monitor (CGM) called the iCan o3 in 70 adults with type 1 or type 2 diabetes. Participants will wear the device for 60 days to see if it improves their blood sugar control, especially the time spent in a healthy range. The goal is to make diabetes management easier and reduce the need for fingerstick tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iCan o3 Continuous Glucose Monitoring (CGM) System (a device that continuously measures blood sugar levels)
What this could lead to: If successful, this could show that the iCan o3 CGM helps people with diabetes better manage their blood sugar levels and reduce fingerstick testing.
What could go wrong: This is a small, short-term study (70 people, 60 days) and may not prove long-term benefits. Risks include skin irritation and delayed glucose readings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS GLUCOSE MONITORING SYSTEM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTINUOUS GLUCOSE MONITORING SYSTEM DIABETES MELLITUS

Contacts and locations

Locations

UZA ANTWERP UZA Dienst Endocrinologie

Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.